Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-040811
Filing Date
2025-05-08
Accepted
2025-05-08 08:10:55
Documents
74
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0239631-10q_protara.htm   iXBRL 10-Q 624079
2 EXECUTIVE EMPLOYMENT AGREEMENT, EFFECTIVE AS OF APRIL 15, 2025, BY AND BETWEEN T ea023963101ex10-6_protara.htm EX-10.6 60663
3 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ea023963101ex10-7_protara.htm EX-10.7 13293
4 CERTIFICATION ea023963101ex31-1_protara.htm EX-31.1 14745
5 CERTIFICATION ea023963101ex31-2_protara.htm EX-31.2 11569
6 CERTIFICATION ea023963101ex32-1_protara.htm EX-32.1 7853
  Complete submission text file 0001213900-25-040811.txt   4812188

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE tara-20250331.xsd EX-101.SCH 54617
8 XBRL CALCULATION FILE tara-20250331_cal.xml EX-101.CAL 40562
9 XBRL DEFINITION FILE tara-20250331_def.xml EX-101.DEF 213705
10 XBRL LABEL FILE tara-20250331_lab.xml EX-101.LAB 432528
11 XBRL PRESENTATION FILE tara-20250331_pre.xml EX-101.PRE 235122
76 EXTRACTED XBRL INSTANCE DOCUMENT ea0239631-10q_protara_htm.xml XML 495632
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 25924004
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)